[CLSTR]
API
< Back to situation

[REVISION HISTORY]

Advancements in metastatic cancer clinical trials

5 recorded revisions of this situation.

What changed

2026-10-29 02:31 UTC → 2026-11-05 00:42 UTC · added removed

Recent phase 3 clinical trials have demonstrated significant survival benefits for various metastatic cancer treatments. In gastroesophageal adenocarcinoma, the HERIZON-GEA-01 trial showed that zanidatamab combined with chemotherapy reduced the risk of death by 24% compared to trastuzumab plus chemotherapy for HER2-positive patients. The Clarity-Gastric01 study found Researchers noted that sonesitatug vedotin (Sone-Ve) reduced adding tislelizumab may provide additional survival benefits, though this requires further evaluation. In the risk field of death by 42% in patients with Claudin 18.2 positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. Additionally, research into biliary tract metastatic triple-negative breast cancer indicates that ivonescimab combined with gemcitabine and cisplatin showed (TNBC), experts are evaluating antibody-drug conjugates (ADCs). The FDA has approved sacituzumab govitecan as a 25% reduction first-line option, both as a monotherapy and in the risk of death, combination with pembrolizumab, while the HARMONi-GI1 trial reported datopotamab deruxtecan has emerged as a median overall survival of 14.9 months using ivonescimab with chemotherapy. In significant option based on the field TROPION-Breast02 trial. Additionally, phase 2 trials of small cell the bispecific antibody pumitamig showed antitumor activity in TNBC, including potential efficacy in cases with brain metastases. Regarding lung cancer, the DeLLphi-305 Phase III trial found that combining tarlatamab with durvalumab reduced the risk of death by 58%. New data presented at the European Society for Medical Oncology (ESMO) congress regarding endometrial 58% in small cell lung cancer confirms (SCLC). In the efficacy of OptiTROP-Lung06 trial, sacituzumab tirumotecan (sac-TMT). In a phase 3 international trial published (sac-TMT) combined with Keytruda reduced the risk of disease progression or death by 51% in ‘The Lancet’, PD-L1-negative non-small cell lung cancer. Pumitamig also showed intracranial objective response rates of 38.2% in SCLC patients. In endometrial cancer, sac-TMT—which targets the TROP2 protein—showed a median overall survival of 19.0 months compared to 12.1 months for standard chemotherapy. This represents chemotherapy, representing a 32% reduction in the relative risk of death and a 41% reduction in the risk of disease progression or death. However, serious side effects were noted, with grade 3 or higher treatment-related side effects occurring occurred in 54.4% of the sac-TMT group. In ovarian cancer research, a phase 1 trial at the Dana-Farber Cancer Institute tested a personalized vaccine called NeoVax. When combined with the immunotherapy drug nivolumab, the vaccine successfully triggered a strong immune response in participants.

Versions

  1. 2026-11-05 00:42 UTC Advancements in metastatic cancer clinical trials
  2. 2026-10-29 02:31 UTC Advancements in metastatic cancer clinical trials
  3. 2026-10-28 19:48 UTC Advancements in metastatic cancer clinical trials
  4. 2026-10-28 17:04 UTC Advancements in metastatic cancer clinical trials
  5. 2026-10-25 18:11 UTC Advancements in metastatic cancer clinical trials
  6. 2026-10-25 16:55 UTC Advancements in metastatic cancer clinical trials

Select a version to see what changed compared to the one before it.